Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial -

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial
Information type: Randomised controlled trials
Source: JAMA Psychiatry
Specialities: Mental health and illness
Summary
Six week RCT (n=333) of adjunctive basimglurant (modified release), an mGlu5-negative allosteric modulator, found no difference on the study’s primary outcome measure, the clinician-rated MADRS change from baseline to end of treatment, vs placebo.
UKMi comment
An editorial notes that like several other recent clinical trials, the high rates of placebo response make it difficult to draw any firm conclusions regarding basimglurant’s true clinical efficacy or the future value of developing novel glutamate modulating drugs.
Related links: Editorial